Volume 17, Issue 39, January - June, 2023

Development and characterization of felodipine fast dissolving tablets

Raghavendra Kumar Gunda^1♦, Suresh Kumar JN², Mansur Ali SK³, Naveena B³, Yamini B³, Priyanka CH³, Sravani L³

¹Associate Professor, Department of Pharmaceutics, Narasaaropeta Institute of Pharmaceutical Sciences, Yellamanda (Po), Narasaraopet, Palnadu (Dt), Andhra Pradesh, India
²Professor cum Principal, Department of Pharmaceutics, Narasaaropeta Institute of Pharmaceutical Sciences, Yellamanda (Po), Narasaraopet, Palnadu (Dt), Andhra Pradesh, India
³Research Scholars, Department of Pharmaceutics, Narasaaropeta Institute of Pharmaceutical Sciences, Yellamanda (Po), Narasaraopet, Palnadu (Dt), Andhra Pradesh, India

^♦Corresponding author
Associate Professor, Department of Pharmaceutics, Narasaaropeta Institute of Pharmaceutical Sciences, Yellamanda (Po), Narasaraopet, Palnadu (Dt), Andhra Pradesh, India
ORCID: 0000-0002-4271-8614

ABSTRACT

Objective: The current study's objective is to develop and characterise fast-dissolving tablets (FDT) for felodipine. Felodipine an excellent calcium channel blocker. It is primarily used to effectively control angina pectoris and hypertension. It has a limited bioavailability after oral administration due to its extremely low solubility in GI fluid. Thus, it is imperative to develop Felodipine appropriate dosage forms in order to ensure consistent bioavailability. Hence, it is necessary to develop appropriate dose forms, such as a mouth-dissolving or disintegrating tablet, in order to obtain improved patient compliance. Methods: Using various quantities of Ac-di-sol & Explotab as Super-disintegrants, FDT formulations of felodipine were prepared utilising the Direct Compression technique. Nine trials were developed and assessed for Pharmaceutical Product Performance. Results: Findings indicate that all formulations meet the acceptance criteria and kinetic modelling was applied to the in-vitro dissolution profiles. Conclusion: The best formulation (F5), which is likewise identical to the marketed product (PLENDIL-5) (f2= 87.35, f1= 1.97), contained 6 mg of Ac-di-sol and 6 mg of Explotab. Formulation (F5) follow first order, whereas release mechanism found to be fickian type (n= 0.449).

Keywords: Felodipine, super-disintegrants, Explotab, Ac-di-sol, Fickian

Drug Discovery, 2023, 17(39), e18dd1916

PDF

DOI: https://doi.org/10.54905/disssi.v17i39.e18dd1916

Published: 12 April 2023